

# DZHK-SOP-B-04

# **Biosample processing**

(Study centre without DZHK Clinical Study Unit)

Version: V1.3

As of: 15.04.2024

Replaced version: V1.2

Of: 19.02.2020

#### Note: Printouts are not subject to the update process!

Change note: Changes to wording Editorial changes

	Scientific author	Scientific review	Approval WGCR	Approval DZHK
			spokesperson	
Name	Tanja Zeller	Ivonne Wallrabenstein	Monika Kraus	Katharina
				Eulenburg
Date				
Signature	This SOP is a tran signatures.	slation from the original G	erman SOP and valid	without

## Table of contents

Та	ble of	contents2
1	Intr	oduction
	1.1	List of abbreviations
	1.2	Objectives
	1.3	Background
	1.4	Terms and definitions
2	DZH	K-set4
3	Req	uirements for biosample collection and documentation4
4	Sam	ple processing and documentation5
	4.1	Specifications
	4.2	Flow Chart
	4.3	Sample processing procedure and documentation in detail6
	4.4	Storage of biosamples
	4.5	Biosample data in SecuTrial <sup>®</sup> 7
	4.6	Sending of biosamples (DZHK-set/Stuy-set)7
	4.7	Processing times and storage - sample qualities7
	4.8	In case of deviations8
5	Lite	rature8
6	Refe	erences to other DZHK-SOPs8
7	Cha	nges8
8	Part	icipating persons

DZHK-SOP-B-04	As of: 15.04.2024	Next review 04/2026
Version: V1.3	Author: T. Zeller	Seite <b>2</b> von <b>9</b>

## **1** Introduction

## **1.1 List of abbreviations**

Abbreviation	Full form
DZHK	German centre for cardiovascular research
EDTA	Ethylene-diamine-tetra-acetic acid
eCRF	Electronic case report form
SOP	Standard operating procedure

## 1.2 Objectives

This standard operating procedure describes the processing and storage of biosamples obtained within the framework of DZHK projects (usually a clinical study, a registry or a cohort) for the establishment of a biosample resource under standardized conditions.

#### Core elements are highlighted in grey in this SOP.

## 1.3 Background

In scientific studies, various approaches are used to examine human biosamples, such as the determination of (circulating) biomarkers, determination of standard laboratory values, OMICs procedures, DNA/RNA extraction or "biomonitoring", for which a high sample quality is the basis. In order to minimize pre-analytical factors, which have a significant influence on sample quality, the steps of collection, processing and storage must be standardized according to DZHK SOPs. This standardization not only ensures that as many of the above-mentioned techniques as possible can still be carried out after long-term storage of the biosamples, but also enables the comparability of the analytical data obtained from the biosamples processed and stored at the different study centres at a later stage.

## 1.4 Terms and definitions

**Biosamples** are e.g. blood, urine, stool and tissue as well as the materials obtained after processing (e.g. plasma, serum, extracted DNA, RNA, stem cells).

#### DZHK-Biobanking<sup>1</sup> for the DZHK Heart Bank

The <u>DZHK Heart Bank</u> combines valuable resources of biosamples, associated clinical data, image data and genomic data, which are collected within the framework of DZHK projects and other projects. The aim is to make a sustainable contribution to research and the improvement of health. The open resource is available for research projects worldwide. DZHK biobanking is carried out with a firmly defined **DZHK**-*set*<sup>2</sup>. The DZHK Heart Bank contains all the DZHK sets gained.

<sup>&</sup>lt;sup>2</sup> Former "DZHK-Basic-Set"

DZHK-SOP-B-04	As of: 15.04.2024	Next review 04/2026
Version: V1.3	Author: T. Zeller	Seite <b>3</b> von <b>9</b>

<sup>&</sup>lt;sup>1</sup> Former "DZHK-Basic-Biobanking"

#### Study biobanking<sup>3</sup> to answer the research question

In addition to the DZHK set, a study-specific sample collection according to this SOP may be necessary. The composition of these *study-sets*<sup>4</sup> as well as the determination of the collection times is up to the responsible Principle Investigator of the respective DZHK project and will be communicated to the participating study centres and scheduled at the initiation event at the latest.

#### SecuTrial®

In addition to documenting the clinical items, the clinical data management system is also used to record a defined biosample data set (via eCRF). Once the data entry is complete, the correctness, completeness and plausibility are confirmed by assigning a Review A and the biosample data of the eCRF is released for transfer to the central laboratory information and management system of the DZHK (DZHK-LIMS).

## 2 DZHK-set

A standardized DZHK-set is taken from each participant of a DZHK project once at the baseline visit (before intervention), provided that the participant has consented. The composition of the DZHK-set is listed below in Table 1. According to the established clinical routines, either BD or Sarstedt tubes can be used.

	Primary	BD		Sarstedt		
	vessel	Volume	number	Volume	number	
	serum	10,0 ml	1	7,5 ml	1	
D7HK_sot	EDTA	10,0 ml	1	7,5 ml	1	
DZIIK-Set	citrate	2,7 ml	1	3,0 ml	1	
	urine	11,0 ml	1	10,0 ml	1	

#### Table 1 Type, volume and number of primary vessels

## **3** Requirements for biosample collection and documentation

The following requirements are needed to carry out sample processing and storage for the DZHK-set and, if applicable, the study-set:

- Centrifuge (refrigerated or non-refrigerated)
- Calibrated pipettes
- Freezer -80°C with connection to monitoring system and fail-safe concept
- Completed biosample consignment bill for sample collection
- Collected biosamples in labelled primary sample containers (DZHK set/study set)
- Aliquot tubes labelled and placed on a 96-well rack (see Fig. 1)

<sup>&</sup>lt;sup>4</sup> Former "Study-specific set "

DZHK-SOP-B-04	As of: 15.04.2024	Next review 04/2026
Version: V1.3	Author: T. Zeller	Seite <b>4</b> von <b>9</b>

<sup>&</sup>lt;sup>3</sup> Former "Study specific biobanking"



Fig. 1: Example of lasered 500  $\mu l$  aliquot tubes from LVL-Technologies.

		1	2	3	4	5	6	7	8	9	10	11	12
Serum (10 x 300µl)	Α												
	В												
EDTA-Plasma (10 x 300µl)	С												
Buffy Coat* (2 x bis 300µl)	D												
	Ε												
Citrate (4 x 300µl)	F												
	G												
Urine (8 x 300µl)	Н												

Fig. 2: Schematic representation of the positions of the aliquot tubes on the rack with sample type -pipetting scheme.

## 4 Sample processing and documentation

## 4.1 Specifications

Biosample processing and documentation must be carried out by trained staff in accordance with the locally applicable specifications in accordance with this SOP. Deviations from the following requirements are documented as a deviation on the biospecimen consignment bill and in SecuTrial<sup>®</sup> (see section 6.4).

The following must also be noted:

- Regular disinfection of work surfaces
- Compliance with current hygiene regulations

DZHK-SOP-B-04	As of: 15.04.2024	Next review 04/2026
Version: V1.3	Author: T. Zeller	Seite <b>5</b> von <b>9</b>

## 4.2 Flow Chart



Fig.4: Overview of the processing of biosamples and documentation.

## 4.3 Sample processing procedure and documentation in detail

#### Confirm receipt of the sample in the laboratory promptly on the biosample consignment bill.

**Centrifugation** of all primary samples takes place after the sample receipt has been confirmed in the laboratory:

- One of the following two options must be used for centrifugation of the primary samples: 2,000 g for 10 minutes OR 3,000 g for 5 minutes.
- The centrifugations can be carried out in refrigerated centrifuges: temperature setting at 18°C
  OR non-refrigerated centrifuges at room temperature (RT): Allow the centrifuge to cool down after each run.
- The type of centrifugation, the time of centrifugation (end of centrifugation) and the condition of each centrifuged primary sample (blood: unremarkable, haemolytic, icteric, lipemic and urine: unremarkable, cloudy, bloody) are documented on the biosample consignment bill.

#### Aliquoting the supernatants after centrifugation:

- Aliquot 300 μl portions into appropriate aliquot tubes.
- The Buffy Coat is obtained from the primary EDTA plasma vessel. If not enough material is available, the aliquot tube can also be filled with less than 300 μl of buffy coat.

In exceptional cases, citrated blood can be used instead of the primary EDTA plasma vessel. In this case, additional documentation is mandatory on the biosample consignment bill in SecuTrial<sup>®</sup> in field 2.14 under "Comment". Enter the following under "Comment": "Citrated blood used".

DZHK-SOP-B-04	As of: 15.04.2024	Next review 04/2026
Version: V1.3	Author: T. Zeller	Seite <b>6</b> von <b>9</b>

2.14.	Anzahl gefüllter Aliquotgefäße	
	Alle 10 Serumgefäße [300µl] gefüllt?	In Oint Oinbekannt Onicht erhoben
	Alle 10 EDTA-Gefäße [300µl] gefüllt?	• ja Onein Ounbekannt Onicht erhoben
	Alle 4 Citrat-Gefäße [300µl] gefüllt?	I a Onein Ounbekannt Onicht erhoben
	Alle 8 Urin-Gefäße [300µl] gefüllt?	Onein Ounbekannt Onicht erhoben
	Alle 2 Buffy Coat-Gefäße [<300µl] gefüllt?	Onein Ounbekannt Onicht erhoben
	Kommentar	

- Seal the aliquot tubes.
- Remove empty aliquot tubes.
- Documentation of the aliquot and the time of storage on the biosample consignment bill.

#### 4.4 Storage of biosamples

- Local documentation of the rack storage location, rack ID and LIMSPSN.
- Store the rack at the documented storage location.
- Do not compact any sample aliquots on the racks. If compaction is necessary, this should only be carried out after consultation with the DZHK support team (<u>biobanking@dzhk.de</u>).

#### 4.5 Biosample data in SecuTrial®

 Digitalization of the documented data from the biosample consignment bill in the eCRF in SecuTrial<sup>®</sup>.

#### 4.6 Sending of biosamples (DZHK-set/Stuy-set)

If you do not have the required storage capacity (-80°C) at your study centre, you can send the **already processed biosamples, i.e. the aliquots**, to the **main study centre**. The shipment will only be processed after consultation with the main study centre. The main study centre is responsible for handling the shipping process, including the necessary documentation steps.

#### 4.7 Processing times and storage - sample qualities

The quality levels are assigned on the basis of the documented times from extraction to storage and the storage conditions. If at least one of the following conditions is met (\*documentation required, see section 6.8), the sample is classified in the respective quality level:

#### DZHK quality level 1

- The primary vessel was not processed within 60 min after sample collection. \*
- The sample aliquot was temporarily stored for 6h or longer at -20°C.\*
- The total duration of biomaterial collection, processing and storage at -80°C was over 240min.

#### DZHK quality level 2

- The sample aliquot was temporarily stored at -20°C for a maximum of 6 hours. \*
- The total duration of biomaterial extraction, processing and storage at -80°C was max. 240 min.

#### **DZHK quality level 3**

DZHK-SOP-B-04	As of: 15.04.2024	Next review 04/2026
Version: V1.3	Author: T. Zeller	Seite <b>7</b> von <b>9</b>

The total duration of biomaterial extraction, processing and storage at -80°C was max. 120min.

#### 4.8 In case of deviations

Any deviations from those described in sections 4.1-4.6 must be documented in SecuTrial<sup>®</sup> under "3. Special features" on the biosample consignment sheet.

3. Besonderheiten		
	Die <u>Primärgefäße</u> wurden über <u>1h</u> zwischengelagert (bei RT). Die <u>Primärgefäße</u> wurden über <u>1h</u> zwischengelagert (bei 4°C). Die <u>Probenaliquote</u> wurden bei -20°C länger als <u>6h</u> zwischengelagert.	

Fig.5: Examples of SOP deviations and their documentation under "3. Special features".

## 5 Literature

Guideline of the German Medical Association for the quality assurance of laboratory medical examinations (in German). Deutsches Ärzteblatt | DOI: 10.3238 / arztebl.2019.rili\_baek\_QS\_Labor20192312

## 6 References to other DZHK-SOPs

The latest available version is valid.

SOP-ID	Title
DZHK-SOP-P-06	Capture-IDAT-Informed Consent
DZHK-SOP-B-01	Biosample collection (Study centres without DZHK clinical study units)
DZHK-SOP-B-05	Sending of biosamples

## 7 Changes

Changes compared to the last version.

Section	Description of the change compared to the previous version.	
Whole document	Wording	
	former biomaterial becomes biosamples	
	former DZHK basic biobanking becomes DZHK-biobanking	
	former DZHK Basic set becomes DZHK-set	
	former study specific biobanking becomes study biobanking	
	former study specific sample set becomes study-set	
Whole document	Editorial changes	

## 8 Participating persons

Name	Role	Contribution
Prof. Dr. Tanja Zeller	First author	Draft
Dr. Ivonne Wallrabenstein	Reviewer	Scientific review

DZHK-SOP-B-04	As of: 15.04.2024	Next review 04/2026
Version: V1.3	Author: T. Zeller	Seite <b>8</b> von <b>9</b>

## Biosample processing (Studycentre without DZHK clinical study unit)

Dr. Ilka Wilhelmi	D7HK main office	Coordination
	DZHK main onice	Coordination

DZHK-SOP-B-04	As of: 15.04.2024	Next review 04/2026
Version: V1.3	Author: T. Zeller	Seite <b>9</b> von <b>9</b>